Go through the installation process, and then launch the application. Press the "New" button, and name your virtual machine. Make sure your "Type" is set to "Microsoft Windows" and your "Version ...

Nintendo has announced a new feature coming to both the Nintendo Switch and Nintendo Switch 2 called Virtual Game Cards that will let users to treat their digital games more like physical ones ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

In short, Virtual Game Cards are a way to share games from your digital library with anyone. They are meant to act exactly like a physical game card, meaning you can “give” it to another ...

Nintendo Virtual Game Card is a new Switch feature arriving in April Virtual Game Cards make it easier for players to lend out their digital games The feature will also be available on Switch 2 at ...

It's called Virtual Game Card and it's coming to Switch 1 in "late April". Here's how it works: once the feature becomes available, any digital purchase made will be added to the associated Switch ...

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Merck MRK announced that it has entered into an exclusive licensing deal with China-based Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for the latter’s investigational oral small-molecule ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.

Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the latest in a series of cross-border deals between Western ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor. In return for the ex-China rights to the drug, dubbed HRS-5346, Merck has ...